Bristol-Myers Squibb Co (XSWX:BMY) Total Stockholders Equity: CHF15,800 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BMY Bristol-Myers Squibb Co XSWX:BMY
75 GF Score
Price CHF51.44
GF Value CHF45.29
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Total Stockholders Equity?

Bristol-Myers Squibb Co XSWX:BMY +1.56% 75 Total Stockholders Equity is CHF15,800 Mil as of Mar. 2026. GuruFocus rates XSWX:BMY with a GF Score™ of 75/100 and a GF Value™ of CHF45.29. The stock has 7 warning signs investors should review.

Bristol-Myers Squibb Co's Total Stockholders Equity for the quarter that ended in Mar. 2026 was CHF15,800 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Bristol-Myers Squibb Co's Book Value per Share for the quarter that ended in Mar. 2026 was CHF7.74. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Bristol-Myers Squibb Co's Debt-to-Equity for the quarter that ended in Mar. 2026 was 2.31.

Bristol-Myers Squibb Co  (XSWX:BMY) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Bristol-Myers Squibb Co's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(15799.536-0)/2041.735
=7.74

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Bristol-Myers Squibb Co's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1972.974 + 34579.791) / 15799.536
=2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Total Stockholders Equity Related Terms

Bristol-Myers Squibb Co Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Total Stockholders Equity Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33,106.27 28,936.43 25,451.06 14,564.29 14,721.13

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15,364.92 14,178.14 14,769.25 14,721.13 15,799.54
XSWX:BMY
75GF Score
Bristol-Myers Squibb Co XSWX:BMY
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of CHF15,800 Mil mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a Total Stockholders Equity of CHF15,800 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Total Stockholders Equity too high?
Bristol-Myers Squibb Co's current Total Stockholders Equity is CHF15,800 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Total Stockholders Equity compare to PFE and GILD?
Bristol-Myers Squibb Co's Total Stockholders Equity of CHF15,800 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Total Stockholders Equity is CHF15,800 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Bristol-Myers Squibb Co (XSWX:BMY) has a current Total Stockholders Equity of CHF15,800 Mil. The stock's GF Value™ is CHF45.29, compared to a current price of CHF51.44 — trading 13.6% above its estimated fair value. The current Total Stockholders Equity is CHF15,800 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Total Stockholders Equity is CHF15,800 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of CHF51.44 is trading 13.6% above its estimated GF Value™ of CHF45.29.

Key valuation signals for XSWX:BMY:

  • Total Stockholders Equity: CHF15,800 Mil
  • GF Value™: CHF45.29 vs. price of CHF51.44 (13.6% above fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
75GF Score

Get the complete analysis for XSWX:BMY

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF51.44
Price
CHF45.29
GF Value